Cervical Cancer (MSK, Gynecologic Oncology 2023)

Overview

Single-center retrospective cohort of 177 patients with cervical cancer (CESC) sequenced at Memorial Sloan Kettering Cancer Center from February 2014 through May 2019. Profiled with MSK-IMPACT to characterize the genomic landscape and identify actionable alterations, with a survival subset (n=97) for OS analysis. Compared against cesc_tcga_pan_can_atlas_2018. PMID:37643132

Composition

  • 177 patients with cervical cancer; histologic subtypes: squamous cell carcinoma (n=69, 39%), usual endocervical adenocarcinoma (n=50, 28%), gastric-type endocervical adenocarcinoma (n=22, 12%), adenosquamous carcinoma (n=21, 12%), and other (n=15, 9%). PMID:37643132
  • 60% primary tumors, 40% metastatic sites. PMID:37643132
  • 80% of tumors HPV-positive (high-risk). PMID:37643132
  • Actionability annotated using OncoKB version 3.1.4. PMID:37643132

Assays / panels (linked)

Papers using this cohort

  • PMID:37643132 — Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets.

Notable findings derived from this cohort

  • Most frequently altered genes: PIK3CA (25%), ERBB2 (12%), KRAS (12%), KMT2C (10%), KMT2D (9%). PMID:37643132
  • KRAS mutations significantly enriched vs. TCGA (12% vs. 5%, P=0.019). PMID:37643132
  • 13% of patients had TMB-high (>10 mut/Mb) tumors; 37% had at least one actionable alteration at OncoKB level 3B. PMID:37643132
  • Oncogenic TP53 mutations and HPV positivity were mutually exclusive: 3.5% of HPV-positive vs. 53.8% of non-gastric-type HPV-negative cases harbored oncogenic TP53 alterations (P=0.00007). PMID:37643132
  • Median OS for survival cohort (n=97): 59.2 months (95% CI: 46.7–89.4). PMID:37643132

Sources

This page was processed by crosslinker on 2026-05-04.